Tandem Retained Earnings Total Equity from 2010 to 2024
| TNDM Stock | USD 49.57 2.47 4.75% |
Retained Earnings Total Equity | First Reported 2014-03-31 | Previous Quarter -853.1 M | Current Value -888.8 M | Quarterly Volatility 182.8 M |
Check Tandem Diabetes financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tandem Diabetes' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.4 M, Interest Expense of 5.8 M or Selling General Administrative of 370.1 M, as well as many indicators such as Price To Sales Ratio of 2.44, Dividend Yield of 0.0 or PTB Ratio of 4.71. Tandem financial statements analysis is a perfect complement when working with Tandem Diabetes Valuation or Volatility modules.
Tandem | Retained Earnings Total Equity |
Latest Tandem Diabetes' Retained Earnings Total Equity Growth Pattern
Below is the plot of the Retained Earnings Total Equity of Tandem Diabetes Care over the last few years. It is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. Tandem Diabetes' Retained Earnings Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tandem Diabetes' overall financial position and show how it may be relating to other accounts over time.
| Retained Earnings Total Equity | 10 Years Trend |
|
Retained Earnings Total Equity |
| Timeline |
Tandem Retained Earnings Total Equity Regression Statistics
| Arithmetic Mean | (469,343,447) | |
| Coefficient Of Variation | (41.26) | |
| Mean Deviation | 175,482,151 | |
| Median | (477,613,000) | |
| Standard Deviation | 193,646,249 | |
| Sample Variance | 37498.9T | |
| Range | 480.5M | |
| R-Value | (0.95) | |
| Mean Square Error | 3999.3T | |
| R-Squared | 0.90 | |
| Slope | (41,100,610) | |
| Total Sum of Squares | 524984.2T |
Tandem Retained Earnings Total Equity History
About Tandem Diabetes Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Tandem Diabetes income statement, its balance sheet, and the statement of cash flows. Tandem Diabetes investors use historical funamental indicators, such as Tandem Diabetes's Retained Earnings Total Equity, to determine how well the company is positioned to perform in the future. Although Tandem Diabetes investors may use each financial statement separately, they are all related. The changes in Tandem Diabetes's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Tandem Diabetes's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Tandem Diabetes Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Tandem Diabetes. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Retained Earnings Total Equity | -656.3 M | -689.1 M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Tandem Diabetes Care using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Additional Information and Resources on Investing in Tandem Stock
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:Check out the analysis of Tandem Diabetes Correlation against competitors. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (2.16) | Revenue Per Share 11.817 | Quarterly Revenue Growth 0.132 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.